<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872818</url>
  </required_header>
  <id_info>
    <org_study_id>14/128</org_study_id>
    <nct_id>NCT02872818</nct_id>
  </id_info>
  <brief_title>Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia</brief_title>
  <official_title>The Effect of Metformin and Medroxyprogesterone Acetate on Apoptotic Signaling Pathways in Wistar-Albino Rats With Induced Endometrial Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kayseri Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kayseri Education and Research Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine apoptotic signaling pathways such as Survivin,
      Bcl-2, Bax, c-Myc and caspase-9 expression levels in rats model with iatrogenic endometrial
      hyperplasia after metformin and medroxyprogesterone acetate administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survivin Gene Expression Levels in Rat Uterine Tissue</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bcl-2 Gene Expression Levels in Rat Uterine Tissue</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bax Gene Expression Levels in Rat Uterine Tissue</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>c-Myc Gene Expression Levels in Rat Uterine Tissue</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Caspase-9 Expression Levels in Rat Uterine Tissue</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Apoptotic Signal Pathways in Endometrial Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medicated with only 4mg/kg 17β estradiol hemihydrate for 20 days to develop endometrial hyperplasia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Having been obtained hyperplasia, the investigators continued medication with 50 mg/kg metformin in addition to 17β estradiol hemihydrate for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medroxyprogesterone acetate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Having been obtained hyperplasia, the investigators continued medication with 1mg/day medroxyprogesterone acetate in addition to 17β estradiol hemihydrate for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17β estradiol hemihydrate</intervention_name>
    <description>4mg/kg/day for 20 days</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Metformin group</arm_group_label>
    <arm_group_label>Medroxyprogesterone acetate group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>50 mg/kg/day last 10 days</description>
    <arm_group_label>Metformin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medroxyprogesterone acetate</intervention_name>
    <description>1mg/kg/day last 10 days</description>
    <arm_group_label>Medroxyprogesterone acetate group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Forty-eight weeks old female Wistar-Albino rats, weighting between 180 and 260 g

        Exclusion criteria.

        We have no exclusion criteria because we examine drugs effects in the experimental rats
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>8 Weeks</minimum_age>
    <maximum_age>10 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erdem SAHİN</last_name>
    <role>Study Director</role>
    <affiliation>Kayseri Training and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kayseri Training and Research Hospital</name>
      <address>
        <city>Kayseri</city>
        <zip>38000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kayseri Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Erdem Sahin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Apoptotic signal pathway</keyword>
  <keyword>Survivin</keyword>
  <keyword>Bcl-2</keyword>
  <keyword>Bax</keyword>
  <keyword>c-Myc</keyword>
  <keyword>Caspase-9</keyword>
  <keyword>endometrial hyperplasia</keyword>
  <keyword>endometrium cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Endometrial Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

